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Summary
Parathyroid hormone (PTH); the principal parathyroid hor-
mone receptor (PTH1R); a G protein-linked heptahelical mem-
brane receptor; and a second heptahelical receptor, the calci-
um-sensing receptor (CaR) through a tightly-regulated en-
docrine feedback system together constitute the principal reg-
ulators of calcium homeostasis.The effectors of the calcium
regulation are coordinated responses in target tissues.These
responses as well as hormone biosynthesis, secretion and
signaling are all under precise genetic control.I n a c t i v a t i n g
mutations in these genes controlling the multi-step process of
calcium homeostasis lead to hypocalcemic disorders, as out-
lined in accompanying articles. 
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Introduction
Secreted by the parathyroid glands, PTH is an important regu-
lator of blood calcium concentration in all terrestrial vertebrate
species from amphibians to mammals. PTH-related peptide
(PTHrP), a slightly larger molecule than PTH, was discovered
more recently through efforts to identify the factor that causes,
when produced in excess by certain tumors, the humoral hy-
percalcemia of malignancy syndrome. In contrast to PTH,
which is produced by discrete endocrine glands, PTHrP is pro-
duced as a paracrine/autocrine factor in many different adult
and fetal tissues and has, unlike PTH, multiple functions (1, 2).
PTH and PTHrP likely evolved from a common ancestral pre-
cursor. Despite this common evolutionary origin, both peptides
share only limited overall amino acid sequence identity, yet at
least their N-terminal regions are sufficiently homologous to en-
able them to bind to and activate a common G protein-coupled
receptor, the PTH/PTHrP receptor (also referred to as PTH1R)
(1). This receptor mediates the most important biologic actions
of both peptides: PTH-dependent regulation of calcium home-
ostasis and PTHrP-dependent regulation of endochondral bone
formation (1, 3).
Calcium homeostasis, the regulation of Ca2 +concentration in
blood within precise limits, depends on two principal regulators,
PTH and the active form of vitamin D, 1,25-dihydroxyvitamin D3
[1,25(OH)2D3] (1). Synthesis and secretion of PTH are stimulat-
ed by any decrease in blood calcium, and conversely, secre-
tion of the hormone is inhibited by an increase in blood calci-
um. This rapid negative feedback regulation of PTH production,
along with the biologic actions of the hormone on different tar-
get tissues, represents the most important homeostatic mecha-
nism for minute-to-minute control of calcium concentration in
the extracellular fluid (ECF) (1-3). In contrast to the rapid ac-
tions of PTH, 1,25(OH)2D3 is of critical importance for long-
term, day-to-day, and week-to-week calcium balance.
At least three distinct, but coordinated actions of PTH increase
the flow of calcium into the ECF and thus increase the concen-
tration of blood calcium (1, 3). Through its rapid actions on the
kidney and bone, which are all mediated through the
PTH/PTHrP receptor and subsequent secondary messages in
specific and highly specialized cells, PTH (1) increases the re-
lease of calcium from bone, (2) reduces the renal clearance of
calcium, and (3) stimulates the production of 1,25(OH)2D3 b y
activating the gene encoding 25-hydroxyvitamin D-1a-hydroxy-
lase (1a-hydroxylase) in the kidney.
Chemistry
The first biologically active extracts from bovine parathyroid
glands were made in 1925 (4), and the content of biologically ac-
tive PTH was assessed by the hypercalcemic properties of ex-
tracts or partially purified preparations. However, it was not until
1959, when Aurbach (5) and Rasmussen and Craig (6) devel-
oped improved extraction procedures, that it became possible to
isolate and purify sufficient quantities to determine the primary
structure of bovine, porcine, and human PTH (7-11). Based on
these amino acid sequences, the PTH(1-34) fragments of the
different species were synthesized, and their biologic activities
were compared in vitro a n d in vivo with those of highly purified
intact PTH from the same species (1, 3). Molecular cloning tech-
niques also led to deduction of the amino acid sequences of rat,
chicken and dog PTH (Fig. 1) (1, 3). Analyses of the complete
genome of fugu fish and zebrafish have provided more recently
veral additional PTH and PTHrP structures.
Extensive sequence homology is present in the known mam-
malian PTH species. All of these molecules consist of a single-
chain polypeptide with 84 amino acids and a molecular weight
of approximately 9400 Da. That of human PTH(1-84) is 9425
Da; fish PTH molecules are shorter. After the original work es-
tablishing that the first 34 amino acids of PTH were sufficient to
produce a fully active synthetic peptide (12), much work has
centered on defining the minimum pharmacophore essential for
biological activity. Assays performed with products of various
combinations of shortened and modified PTH ligands and mu-
tagenized receptors, as well as generation of a fusion protein
consisting of ligand substituted for a portion of the receptor ex-
tracellular domain (tethered receptor) have defined a much
smaller minimum chain length of PTH peptide needed for bio-
logical activity (Fig. 2).
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The activity of native PTH(1-14), which is quite weak, is im-
proved 100,000-fold by the modification indicated in Figure 2.
These shorter peptides have been shown to be active in vivo
as well, causing hypercalcemia and being anabolic on bone, al-
though their potency is much less than that of PTH(1-34). Us-
ing the various approaches, it has been established that pep-
tides as short as PTH(1-9) (tethered constructs) or highly-modi-
fied peptides as short as PTH(1-10), tested as free peptides,
are active in vitro.
PTH biosynthesis and intraglandular processing
During synthesis of the hormone precursor, the prepro-PTH
molecule, the signal sequence from the PTH gene located on
chromosome 11, which comprises the 25 amino acids con-
tained in the “pre” sequence, is cleaved off after entry of the
nascent peptide chain into the intracisternal space bounded by
the endoplasmic reticulum. A heterozygous mutation in this
leader sequence changes a cysteine to an arginine at position -
8 and thus impairs processing of prepro-PTH to pro-PTH. This
mutation has been identified as the most plausible molecular
cause of an autosomal dominant familial form of hypoparathy-
roidism (13). Although it remains uncertain how this missense
mutation in one allele can cause a dominant disorder, it illus-
trates the importance of the signal peptide in normal process-
ing of the hormonal precursor.
Regulation of PTH secretion
A large number of factors modulate PTH secretion in vitro (14),
but most of these factors are not thought to control hormonal
secretionin vivo in a biologically relevant manner. Factors that
are physiologically meaningful regulators of PTH secretion in-
clude the extracellular ionized calcium concentration itself
( C a2 +), 1,25(OH)2D3, and the level of extracellular phosphate
ions. Of these three, Ca2+ is most important in the minute-to-
minute control of PTH secretion. The actions of 1,25(OH)2D3
and phosphate ions on the secretion of PTH probably result, at
least in part, from their effects on hormonal biosynthesis rather
than secretion (14).
The molecular mechanism underlying Ca2+-regulated PTH se-
cretion involves activation of a G protein-coupled cell surface
C a2 +-sensing receptor (abbreviated as CaR or sometimes as
CaSR). The CaR mediates the inhibitory actions of Ca2 + o n
PTH secretion, parathyroid cellular proliferation and probably
also on PTH gene expression (14). In the kidney, the CaR, pre-
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Figure 1 - Alignment of amino acid sequences of typical mammalian and chicken PTH (left) and PTHrP species (right). Conserved residues are shad-
ed; numbers indicate positions of amino acids in the mammalian peptide sequences. (Reproduced with permission from Jüppner H, Potts JT Jr: The
roles of parathyroid hormone and parathyroid hormone-related peptide in calcium metabolism and bone biology: their biological actions and recep-
tors. In, Fray J (editor): Handbook of Physiology - Endocrine Regulation of Water and Electrolyte Balance. UK: Oxford University Press, 1997).
Figure 2 - The PTH(1-14) pharmacophore. Shown is the native (rat)
PTH(1-14) sequence and some of the activity-modifying substitutions
identified in structure-activity relationship studies performed on the
PTH(1-14) peptide. The six substitutions depicted above the sequence
enhance activity by as much as 100,000-fold when combined and as
assessed in in vitro cell-based assays of camp formation. The Bpa2
substitution shown below confers antagonist properties to the peptide.
Within the PTH(1-14) scaffold, the (10-14) region has been found to be
tolerant of many amino acid substitutions, whereas the (1-9) region is
relatively intolerant and is thus thought to contain the minimum agonist
pharmacophore of the ligand. The (1-9) region is the current minimum
chain length pharmacophore. Non-encoded amino acids include amino-














sent in the cortical thick ascending limb of the nephron, medi-
ates direct, high Ca2 +-induced inhibition of the tubular reab-
sorption of Ca2+and Mg2+(14). Therefore, raising Ca2+both di-
rectly increases renal calcium excretion and reduces PTH se-
cretion.
There are hypercalcemic (e.g., familial hypocalciuric hypercal-
cemia and neonatal severe hyperparathyroidism) (15) and
hypocalcemic (i.e., autosomal dominant hypocalcemia) (16)
disorders caused by inactivating versus activating mutations of
the CaR, respectively. Another cause of primary hypoparathy-
roidism, therefore, is the occurrence of activating mutations in
the CaR, a very difficult syndrome to treat because of the ex-
cessive urinary calcium excretion which worsens with therapy
using vitamin D analogues and high oral calcium.
PTH-dependent regulation of mineral ION homeostasis
mediated through the PTH/PTHrP receptor 
(type 1 receptor)
PTH maintains blood calcium concentration within narrow limits
through its actions on the kidney and bone. In bone it stimu-
lates the release of calcium and phosphate, and in the kidney it
enhances renal tubular reabsorption of calcium (via the CaR
receptor), stimulates the urinary excretion of phosphate and in-
creases 1,25(OH)2D3 production--thus increasing, albeit indi-
rectly, intestinal absorption of calcium (and phosphate). These
direct and indirect endocrine actions of PTH are mediated
through the PTH/PTHrP receptor (PTH1R), a G protein-cou-
pled receptor that is abundantly expressed in cells in both ma-
jor target tissues of bone and kidney (1, 3).
PTH is of major importance for maintaining normal blood calci-
um levels, but it is not the principal regulator of the serum
phosphate concentration, which appears to depend upon spe-
cific phosphaturic factors, such as FGF23 (17). However, when
PTH causes an increase in bone resorption (as might occur
with prolonged dietary calcium deprivation), both calcium and
phosphate increase simultaneously in the blood. Although cal-
cium is needed, phosphate is not and would in fact minimize
the benefit of increasing supplies of calcium. Phosphate, there-
fore, is best excreted, which is mainly accomplished by a PTH-
stimulated increase in renal phosphate clearance. The potent,
PTH-dependent reduction in renal phosphate reabsorption oc-
curs in both the proximal and distal tubules (18), but the proxi-
mal effects of the hormone are quantitatively more important
(19). This failure to excrete phosphate appropriately due to de-
ficiencies in PTH responsiveness selectively in renal cortical
sites, including proximal tubules, is a major contributor to the
hypocalcemia seen in pseudohypoparathyroidism.
Recent evidence suggests that the scaffold protein NHERF-1
(Na+/H+-exchanger regulatory factor) regulates the sodium-de-
pendent phosphate co-transporter, NPT2, that mediates the
phosphaturic actions of PTH via direct interactions with the C-
terminus of the transporter (20). NHERF-1 promotes apical lo-
calization of NPT2 in opossum kidney cell models (21). Fur-
thermore, targeted disruption of NHERF-1 in mice results in a
decrease in NPT2 localization to the brush-border of the proxi-
mal tubule and renal phosphate wasting (22). Through a still
poorly-defined mechanism, PTH induces internalization and
lysosomal degradation of NPT2 (21), thereby promoting phos-
phate excretion.
Actions of PTH on bone
PTH affects a wide variety of the highly specialized bone cells,
including osteoblasts, osteoclasts, and stromal cells. Some of
these effects reflect direct actions of PTH; others are indirect
and mediated in an autocrine/paracrine manner through factors
released by cells expressing PTH/PTHrP receptors that regu-
late the activity of yet other cells that lack these receptors
(such as osteoclasts) (1, 3).
Considerable progress has been made in elucidating the
mechanisms through which bone cells respond to PTH and to
other autocrine/paracrine factors. The major pathway for calci-
um release from bone involves osteoclasts, the principal cells
capable of resorbing bone; osteoclasts undergo multiple cellu-
lar changes involving the activation of cellular transporters and
pumps, as well as the secretion of enzymes such as cathepsin
K and collagenases.
Osteoblasts express the PTH/PTHrP receptor most abundantly
and show the most vigorous response to the hormone (1, 3,
23). A remarkable number of cellular activities of osteoblasts
are influenced by PTH, including cellular metabolic activity, ion
transport, cell shape, gene transcriptional activity, and secre-
tion of multiple proteases; cellular proliferation/differentiation
events that result in mature osteoblasts are also affected by
PTH (1, 3). Many other factors also affect osteoblast function
and bone formation. Continuous PTH administration in vivo re-
s lts in decreased bone mass, whereas intermittent administra-
tion of PTH leads to an increase (24). Further exploration of the
cellular mechanisms whereby intermittent PTH administration
selectively enhances bone formation is critical for understand-
ing the hormone's therapeutic effects as a bone anabolic agent
(a surprising but pharmacologically important paradox) (25).
To stimulate bone resorption, PTH signals to osteoclasts indi-
rectly through osteoblasts which, unlike osteoclasts, clearly have
abundant PTH/PTHrP receptors on their surface and respond to
the hormone with a dramatic change in cellular activity. 
Several cytokines are central in the paracrine signaling cas-
cade from osteoblasts and/or osteoblast precursors to
r cruit/activate osteoclasts. These molecules include the re-
ceptor activator of nuclear factor k b (RANK) ligand (RANKL)
(26-29), a membrane-associated protein with homology to the
family of tumor necrosis factors (TNFs) that induces – upon
cell-to-cell contact and in the presence of macrophage colony-
stimulating factor – the differentiation of osteoclast precursors
into mature bone-resorbing osteoclasts (26-29). These effects
of RANKL are mediated through RANK, a member of the TNF
receptor family that is expressed on osteoclast precursors.
However, RANKL also interacts with osteoprotegerin (OPG), a
soluble decoy receptor with homology to the TNF receptor fam-
ily (30); this molecule acts as the inhibitory arm of osteoclast
regulation. Transgenic expression of osteoprotegerin in mice
leads to impaired osteoclastogenesis and thus to osteopetro-
sis, whereas ablation of the osteoprotegerin gene through ho-
mologous recombination in mice results in osteoporosis associ-
ated with arterial calcifications.
PTH, as well as other cytokines such as interleukin-6, inter-
leukin-11, prostaglandin E2 and 1,25(OH)2D3, has an important
role in the paracrine stimulation of osteoclast formation and
can stimulate directly the production of RANKL by osteoblasts
and suppress OPG production (1, 3). Cellular responses in-
volved in bone resorption include the development of vit-
ronectin-mediated anchorage of osteoclasts to the bone sur-
face, acidification of the circumscribed and sealed-off extracel-
lular environment that is created between the osteoclast and
bone, and in addition, the secretion of a variety of proteases
and other enzymes.
Receptors for PTH and PTHrP
Because of the diverse actions of PTH, which were shown to
involve multiple signal transduction mechanism, it was initially
thought that several different receptors must mediate the
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pleiotropic actions of this peptide hormone, but only one recep-
tor type seems to mediate many of these actions. This
PTH/PTHrP receptor is now known to interact similarly with
PTH and PTHrP and to activate several distinct second mes-
senger pathways--including adenylate cyclase/PKA, phospholi-
pase C (PLC)/protein kinase C (PKC), and calcium transcellu-
lar fluxes.
Most of the endocrine actions of PTH and the paracrine/au-
tocrine actions of PTHrP are mediated through this single
PTH/PTHrP receptor. Subsequent studies, however, led to the
isolation of two other novel, closely related G protein-coupled
receptors. One of these receptors, the PTH2 receptor
(PTH2R), mediates the actions of TIP39 (tubular infundibular
peptide of 39 amino acids), a more recently discovered hypo-
thalamic peptide; human PTH2R, but not the rat receptor ho-
mologue, is also efficiently activated by PTH. The second novel
receptor, the PTH3 receptor (PTH3R) (which seems not to be
present in the human or other mammalian genomes), has been
cloned from zebrafish, and it responds to human PTHrP more
efficiently than to human PTH. Furthermore, there is both func-
tional and physicochemical evidence of additional receptors
that interact with more carboxyl terminal fragments of PTH and
PTHrP; however, cDNAs encoding these novel receptors have
not yet been isolated.
The PTH/PTHrP receptor (PTH1R) belongs to a distinct family
of G protein-coupled receptors (Family B). The first cDNAs en-
coding mammalian PTH/PTHrP receptor species were isolated
through expression cloning techniques from opossum kidney
cells and rat osteoblast-like osteosarcoma cells. Subsequently,
cDNAs encoding human, mouse, rat, chicken, porcine, dog,
frog, and fish PTH/PTHrP receptors were isolated (1, 3).
Scores of synthetic peptide fragments and analogs have been
used to explore the structure-activity relations in the hormone.
The quantification of ligand-binding affinity through radiorecep-
tor studies showed that receptor affinity progressively de-
creased as PTH(1-34) was truncated either from the amino-ter-
minus or the carboxyl-terminus. Furthermore, fragments such
as PTH(7-34), which show little or no agonist activity, proved to
inhibit the actions of PTH(1-34), at least when present in high
molar excess. These early studies that broadly defined the
structural requirements for biologically active PTH and sug-
gested that the receptor-binding and -activation functions
resided in separable domains, provided the groundwork for the
subsequent intensive study of structure/activity relations (SAR)
for hormone and receptor.
A general scheme of interaction between ligand and receptor,
which may apply to the entire class B family of peptide hor-
mone-binding G protein-coupled receptors, was established. A
hybrid ligand, calcitonin(1-11)/PTH(15-34), was shown to acti-
vate a chimeric calcitonin-PTH/PTHrP receptor. The chimeric
receptor contained the amino-terminal, extracellular domain
(the N domain) of the PTH/PTHrP receptor fused to the portion
of the calcitonin receptor containing the seven membrane-em-
bedded helices, the connecting loops, and carboxy-terminal tail
(the juxtamembrane or J domain).
The data confirmed that for PTH, the amino-terminus of the lig-
and interacts with the J domain of the receptor, while the car-
boxyl-terminus of the ligand interacts with the N domain. This
hypothesized mode of binding inferred from functional analyses
has now largely been verified and extended by the more direct
method of photoaffinity cross-linking analysis. In conventional
radioreceptor assays, the PTH(1-14) fragment was unable to
inhibit the binding of 1 2 5I-PTH(1-34) to the intact PTH/PTHrP
receptor, suggesting that the interaction between the N-termi-
nal residues of PTH and the membrane-embedded portion of
the receptor, was of low-affinity. This observation further led to
the conclusion that the intrinsic signaling efficacy of the native
PTH(1-14) fragment must be high, such that even a brief en-
counter with the receptor can trigger signal transduction. These
considerations had suggested that it might be possible to modi-
fy the PTH(1-14) fragment to improve affinity and to thus obtain
potent agonist ligands of minimum peptide chain length. A se-
r es of structure-activity relationship studies was thus conduct-
ed on the PTH(1-14) scaffold, and this led to the identification
of a number of activity-enhancing substitutions at several
residue positions (i.e., 1, 3, 10, 11, 12 and 14), which, when
combined, led to substantial improvements in potency (31).
Among the amino acid changes tested were the paired subsitu-
tions of the conformationally constrained amino acid, a -amino-
isobutyric acid (Aib) at positions 1 and 3, that together provided
 100-fold gain in potency and, combining these with other ac-
tivity-enhancing substitutions at positions 10-14, collectively re-
ferred to as the “M” substituions, resulted in analogs such as
[ A i b1 , 3, G l n1 0, H a r1 1, A l a1 2, T r p1 4]PTH(1-14) or [Aib1 , 3, M ] P T H ( 1 - 1 4 )
that are as much as 100,000-fold more potent than PTH(1-14)
and nearly as potent as PTH(1-34) for cAMP formation in cell-
based assays utilizing the intact PTH receptor. These analogs
constitute the minimum requisite pharmacophore, as noted in
Figure 2. The enhanced analogs also exhibited high (nanomo-
lar) potency on PPR-delNt, the J domain of the receptor The
substitutions also conferred activity to even shorter peptides,
previously found to be inactive, such as PTH(1-10) (31), and
extending the analogs C-terminally to position 20 or 21 and in-
cluding the substitution of Glu19® Arg further enhanced poten-
cy on both the wild-type PPR and on PPR-delNt. 
These studies demonstrate the critical role for the amino-termi-
nal residues of PTH (and PTHrP) in activating the PTH/PTHrP
receptor, and are fully consistent with the strong evolutionary
conservation of this portion of PTH and PTHrP over a wide
range of verterbrate species. Nevertheless, the very weak sig-
naling potency of unmodified PTH(1-14), relative to that of in-
tact PTH(1-34) (EC5 0 s=200 m M and 2 nM, respectively) high-
lights the crucial role that the carboxyl-terminal amino acid
residues of PTH(1-34) play in the overall biological activity of
the native hormone in providing important binding energy for
PTH. It is now clear that the C-terminal portion of PTH(1-34)
provides critical docking interactions for the receptor and there-
by enables the otherwise poorly binding amino-terminal domain
of the ligand to associate with the J domain of the receptor--
i.e., the extracellular loops (ECLs) and extracellular ends of the
ransmembrane helical domains (TMs). As one test of such a
tethering role for the carboxyl-terminal domain of PTH(1-34),
PTH analogs were synthesized in which the PTH(1-9) seg-
ment, representing the essential elements of the PTH agonist
pharmacophore, was linked by a five-residue glycine spacer to
the PTH(15-31) domain; although the resulting peptide was
less potent than PTH(1-34) (EC50s ~ 100 nM and 1 nM, respec-
tively), the Gly-linker analog achieved the same maximal cAMP
response as that induced by PTH(1-34), whereas, in contrast,
the individual fragment peptides, PTH(1-9) and PTH(15-31),
were inactive (31). In another test of the thethering concept,
he PTH(1-9) sequence was directly linked, via site directed
mutagenesis methods, to the J domain of the PTH/PTHrP re-
ceptor at a site (Glu-182) just N-terminal of the extracellular
end of TM1; COS-7 cells transfected with this “tethered”
PTH(1-9)/PTH/PTHrP receptor construct exhibited intracellular
cAMP levels that, in the absence of added agonist ligand, were
approximately equivalent to those seen in cells transfected with
the wild-type PTH/PTHrP receptor and maximally treated with
PTH(1-34) and further supporting the schema shown in Figure
2 (31).
Further studies will lead to a more definitive model of the mole-
cular mechanisms by which PTH binds to and activates its re-
ceptor. The overall data so far are fully consistent with the two-
s t  binding mechanism of interaction, shown in Figure 4. The
C-terminal domain of PTH(1-34) binds to the N-terminal do-














main of the receptor, and this high affinity interaction enables
the subsequent, low affinity interaction of the N-terminal do-
main of the ligand with the juxtamembrane region of the recep-
tor which, in turn, induces or stabilizes the conformation of re-
ceptor and ligand (31). The overall interaction is likely to be a
multi-step, concerted process, as discussed for other GPCRs
(32), and such a process could enable the formation of differ-
ent activated states of the PPR each of which might activate a
distinct set of signal transduction pathways and/or post-activa-
tion regulatory mechanisms. Indeed, recent functional studies
on the signaling pathways and desensitization mechanisms
used by the PTH/PTHrP receptor provide evidence to support
the notion that multiple activation states are possible for the
PTH/PTHrP receptor.
This brief summary of the current state of knowledge about the
molecular and cellular biology of PTH actions serves as a
background for understanding the etiologies of hypoparathy-
roidism as discussed in the subsequent articles. Several exam-
ples of such causes of hypocalcemia due to defects in PTH-
mediated calcium homeostasis have been mentioned above,
such as interference with intracellular biosynthesis and pro-
cessing of the hormonal precursor (mutation in the “pre” se-
quence) or interference at the post-receptor response to PTH
when responses are defective due to inactivating mutation in
specific G proteins (pseudohypoparathyroidism). Mutational
changes in the G protein-coupled receptor, CaR, that regulates
PTH secretion and modulates renal calcium excretion (also
mentioned above) constitute a third example.
The multi-step process in the calcium homeostatic system in-
volving several key molecules (including hormone, hormone re-
ceptor, and CaR) and complex cellular responses in hormone
target tissues (bone and kidney) can be impaired at any step in
its complex genetic control extending from failed parathyroid
gland organogenesis (hence, impaired or absent hormone pro-
duction) to inadequate peripheral responses (defective recep-
tor or G protein production). In contrast to the prevalence of hy-
percalcemic disorders, diseases associated with hypocalcemia
are much rarer; this may be explained by negative evolutionary
s lection pressure and perhaps even some still unappreciated
redundancies in the system. Fortunately, given the burden of
symptoms associated with hypoparathyroidism, many patients
can be adequately treated, as explained in the accompanying
articles.
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